<DOC>
	<DOCNO>NCT01155219</DOCNO>
	<brief_summary>This phase IV study aim assess safety efficacy intra ocular pressure Geltim LP® 1 mg/g ( 0.1 % unpreserved timolol maleate gel ) glaucomatous patient initially treat stabilised monotherapy Xalatan® ocular objective sign intolerance prostaglandin eye drop .</brief_summary>
	<brief_title>Safety , Efficacy Assessment Geltim LP® 1 mg/g Ocular Hypertensive Glaucomatous Patients .</brief_title>
	<detailed_description>The primary objective compare safety efficacy Geltim LP® 1mg/g eye drop versus Xalatan® eye drop respect : The assessment ocular tolerance : - Ocular symptom - Objective ocular sign . The maintain IOP efficient lower effect . Comparison 2 study product mean basal IOP 12 week treatment period ( 84 day ±7 ) .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>Written inform consent . Association 4 follow criterion : 1 . Bilateral primary open angle glaucoma bilateral ocular hypertension already treat control monotherapy Xalatan® ( 1drop per day ) , 2 . With local intolerance sign . Presence severe objective ocular sign . Any ocular hypertension primary ocular hypertension primary chronic open angle glaucoma ( congenital , angle closure glaucoma , secondary glaucoma ) . Absolute defect ten degrees central point visual field . Best far correct visual acuity ≤ 1/10 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Bilateral Glaucoma</keyword>
	<keyword>Bilateral ocular hypertension</keyword>
	<keyword>Bilateral primary open angle glaucoma</keyword>
	<keyword>Bilateral ocular hypertension already treat control mono-therapy Xalatan® ( 1drop per day )</keyword>
	<keyword>With local intolerance sign least one eye</keyword>
</DOC>